Positive Results of STK-001 in Dravet, Zavegepant Meets Primary End Points, FDA Accepts NDA of Zilucoplan for Myasthenia Gravis
Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD